Malaria is a vector-borne disease caused by Plasmodium infection through the bite of Anopheles or transfusion of the blood of those with malaria parasites, highly prevalent in tropical regions, especially in Africa, characterized by periodic regular attacks, generalized chills, fever, and hyperhidrosis. It is estimated that a total of 216 million people worldwide had been infected with malaria in 2016, and 455,000 people died of malaria, most of whom were children under 5 years of age.

Currently, vector control is the major prevention of malaria, that is killing mosquitoes or preventing mosquito bites, which depends on large amounts use of insecticides. However, in recent years, insecticide-resistant mosquitoes have emerged in many countries, posing great challenges in control efforts.

The malaria vaccinedevelopmentstill remains extremely difficult, and most malaria vaccines cannot pass preclinical trials. There is currently only one malaria vaccine in the world, RTS, S/AS01 (RTS, S), for young children aged 5 to 17 months,which requires four injections and can only achieve 39% effectiveness. It targets P. falciparum, the world's deadliest malaria parasite. Large-scale clinical trials of children who received four doses of the vaccine demonstrated that it prevented about 40% malaria cases within four years. But, how about adults or children elder than 17 months? How can they deal with the horrible malaria?

Fortunately, in 2020, a malaria vaccine capable of providing 100% protection against malaria will be tested for the first time in a large-scale clinical trial conducted in Bioko Island to study its effectiveness for the ages of 2 and 50. The researcher said that the trail was to provide the efficacy and safety data needed for regulatory approval of the vaccine.In laboratory studies, this vaccine called PfSPZ has been shown to be the most effective malaria vaccine developed so far, able to provide complete protection to healthy volunteers.

The PfSPZ vaccine works by eliciting an immune response to P. falciparumcomposed of sporozoites (SPZ), a stage of the Plasmodium life cycle that infected mosquitoes inject into the human body when they bite, in whichbillions of sporophytes are isolated and purified from cultured mosquitoes. It is known for its unique use of the entire parasite as the active ingredient; since most candidate malaria vaccines include only a small number of genetically engineered parasite proteins. The abundance of proteins in the entire parasite vaccine explains why such a strong immune response is triggered.

It’s delighted to witness the emergence of a novel malaria vaccine but there is still a long way before marketing. To support global researchers to concentrate on their vaccine project in a timely manner, Creative Biolabs, a US-based vaccine service provider, has announced a series of Parasitic Vaccines development services to prevent parasitic diseases, such as malaria. Through the combination of traditional and the latest technology, scientists are seasoned at identifying and producing appropriate protective antigens to providemultiple vaccine types, including live vaccines, killed vaccines, subunit and recombinant vaccines, and simultaneously guarantee a customized service within a short turnaround time.